Industry Intelligence
Daily intelligence on pharma manufacturing — CDMO and contract manufacturing moves, GMP compliance and FDA warning letters, facility investment, and production capacity across the global pharmaceutical supply chain.
Despite price cuts and government programs, out-of-pocket GLP-1 costs remain prohibitive for most patients. New data reveals a fundamental affordability
Read More
August 28, 2026 — BioNTech and Genentech terminated the Phase 2 trial of autogene cevumeran (BNT122) in resected colorectal cancer
Read More
The FDA approved Mimrylo (rusfertide), a first-in-class hepcidin-mimicking therapy that fundamentally changes how polycythemia vera is managed, offering 76.9% of
Read More
A personalized mRNA cancer vaccine beat Keytruda alone in a Phase 3 trial, slashing melanoma recurrence risk by up to
Read More
Definium’s DT120 hit its primary endpoint in a Phase 3 anxiety trial, marking the psychedelics developer’s second late-stage win in
Read More
The FDA has approved Tauklarify, a new PET imaging tracer that detects tau tangles in patients being evaluated for Alzheimer’s
Read More
Novo’s oral Wegovy has plateaued around a third of total scripts, while Lilly’s Foundayo keeps notching new weekly highs on
Read More
India has inspected nearly 90% of its cough syrup manufacturers and taken 950+ regulatory actions — here’s what buyers sourcing
Read More
FDA’s new GDUFA IV proposal keeps the 10-month review target and adds real incentives for domestic generic drug manufacturing. The
Read More
Nearly half of biopharma companies still can’t find CDMO capacity — even as sponsors turn their own plants into contract
Read More